Progress of differential expression of SOX11 in mantle cell lymphoma
10.3760/cma.j.issn.1009-9921.2018.05.015
- VernacularTitle: 套细胞淋巴瘤中SOX11差异性表达的研究进展
- Author:
Jingjing YANG
1
;
Zhiling YAN
;
Kailin XU
Author Information
1. Department of Hematology, the Affiliated Hospital of Xuzhou Medical University, Xuzhou 221002, China
- Publication Type:Review
- Keywords:
Lymphoma, mantle-cell;
SOX11;
Molecular targeted therapy;
Prognosis
- From:
Journal of Leukemia & Lymphoma
2018;27(5):308-311
- CountryChina
- Language:Chinese
-
Abstract:
Overexpression of CCND1 and t (11;14) (q13;q32) chromosomal translocation are important markers in mantle cell lymphoma (MCL). However, part of MCL lacks the expression of CCND1. SOX11 can be used as a biomarker for its overexpression in CCND1-negative MCL. SOX11 is a neurogenic transcription factor, and its overexpression is closely related to histone modification and DNA methylation. Differential expression of SOX11 in MCL is closely related with the plasma cell differentiation, and there is a relationship between the prognosis and survival time of MCL. SOX11 cDNA is more sensitive than conventional methods for the detection of minimal residual disease (MRD). With further research of SOX11, it will become an important basis of diagnosis and prognosis in MCL, and can provide a new method for targeted therapy of MCL.
